Drug Trial Radar · NCT00126412
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Last checked: Nov 20, 2026Latest source record: May 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Aug 2, 2005
Primary completion
Sep 27, 2006
Study completion Sep 27, 2006
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Conditions
- Pheochromocytoma
- Neuroblastoma
Interventions
123I-mIBG (meta-iodobenzylguanidine)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- - To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.